Cost considerations in the treatment of colorectal cancer

PharmacoEconomics

Volumn 25, Issue 7, 2007, Pages 537-562

  Jansman, Frank G A ^a,b   Postma, Maarten J ^a   Brouwers, Jacobus R B J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Isala Klinieken ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; RALTITREXED; TEGAFUR; UFT;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION COST; HUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; UNITED STATES;

EID: 34447263280     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725070-00002     Document Type: Review

References (81)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87
2. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005; 365: 153-65
3. Redaelli A, Cranor CW, Okano GJ, et al. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003; 21: 1213-38
4. Sobin LH, Wittekind C. UICC: TNM classification of malignant tumours. 6th ed. London: John Wiley & Sons, 2002
5. Greene FL, Balch CM, Fleming ID, et al. AJCC cancer staging handbook. 6th ed. New York (NY): Springer, 2002
6. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
9. Ehrlichman C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med 2004; 351: 391-2
10. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004; 350: 2406-8
11. Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-9
12. Rajpal S, Venook AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol 2006; 4: 124-32
13. Grem JL. Mature results of adjuvant colon cancer trials from the fluorouracil-only area. J Natl Cancer Inst 2004; 96: 727-9
14. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1773-5
15. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20: 3999-4005
16. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-8
17. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev 2006; 32: 1-8
18. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-5
19. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14
20. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44
21. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51
22. Mayor S. NICE rules on chemotherapy drugs for colon and breast cancer. BMJ 2006; 332: 1052
23. Maroun JA, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003; 21: 1039-51
24. Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005; 25: 563-76
25. Limat S, Bracco-Nolin CH, Legat-Fagnoni C, et al. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. Eur J Health Econ 2006; 7: 107-13
26. Focan C. Pharmaco-economic comparative evaluation of combination chronotherapy vs standard chemotherapy for colorectal cancer. Chronobiol Int 2002; 19: 289-97
27. Ward S, Kaltenthaler E, Cowan J, et al. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003; 7: 1-93
28. Ward SE, Kaltenhaler E, Cowan J, et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006; 95: 27-34
29. Jansman FGA, Postma MJ, Van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in The Netherlands. Clin Ther 2004; 26: 579-89
30. Hieke K, Kleeberg UR, Stauch M, et al. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ 2004; 5: 270-3
31. Hale JP, Cohen DR, Maughan TS, et al. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer 2002; 86: 1684-90
32. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. Pharmacoeconomics 2000; 17: 361-70
33. Norum J, Balteskard L, Edna TH, et al. Raltitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. J Chemother 2002; 14: 301-8
34. Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005; 104: 1871-84
35. Earle CC, Kwok A, Scott Gazelle G, et al. Two schedules of second-line irinotecan for metastatic colon carcinoma: economic evaluation of a randomized trial. Cancer 2004; 101: 2533-9
36. Lloyd-Jones M, Hummel S, Bansback N, et al. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001; 5: 1-128
37. Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterol 2003; 50: 1903-9
38. Levy-Piedbois C, Durand-Zaleski I, Juhel H, et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000; 11: 157-61
39. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002; 86: 1677-83
40. Iveson TJ, Hickish T, Schmitt C, et al. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999; 35: 1796-804
41. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-9
42. Groener MGH, Van Ineveld BM, Byttebier G, et al. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 283-8
43. Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997; 8: 65-70
44. Monz BUM, König HH, Leidl R, et al. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole ad adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics 2003; 21: 709-19
45. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 1997; 89: 790-5
46. Durand-Zaleski I, Earlam S, Fordy C, et al. Cost-effectiveness of systemic and regional chemotherapy for treatment of patients with unresectable colorectal liver metastases. Cancer 1998; 83: 882-8
47. Jansman FGA, Postma MJ. Costs of chemotherapy in the treatment of colorectal cancer. Eur J Health Econ 2006; 7: 145-6
48. Matasar MJ, Sundararajan V, Grann VR, et al. Managing of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging 2004; 21: 113-33
49. Van den Hout WB, Van den Brink M, Stiggelhout AM, et al. Cost-effectiveness analysis of colorectal cancer treatment. Eur J Cancer 2002; 38: 953-63
50. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long-term survivors of colorectal cancer. Am J Gastroenterol 2002; 97: 440-5
51. Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 52-8
52. Kerrigan M, Howlader N, Mandelson MT, et al. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care 2005; 43: 1043-8
53. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997; 18: 51-76
54. Seifeldin R, Hantsch JJ. The economic burden associated with colon cancer in the United States. Clin Ther 1999; 21: 1370-9
55. Etzioni R, Ramsey SD, Berry K, et al. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ 2001; 10: 245-56L
56. Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999; 37: 1249-59
57. Yabroff KR, Warren JL, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care 2005; 43: 640-8
58. O'Brien BD, Brown MG, Kephart G. Estimation of hospital costs for colorectal cancer care in Nova Scotia. Can J Gastroenterol 2001; 15: 143-7
59. Delco F, Egger R, Bauerfeind P, et al. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland. Aliment Pharmacol Ther 2005; 21: 615-22
60. Bouvier V, Reaud JM, Gignoux M, et al. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Departement, France. Eur J Health Econ 2003; 4: 102-6
61. Geddes M, Carli S, Ercolanelli M, et al. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82: 210-4
62. Audisio RA, Cazzaniga M, Robertson C, et al. Elective surgery for colorectal cancer in the aged: a clinical-economical evaluation. Br J Cancer 1997; 76: 382-4
63. Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer 1999; 35: 1789-95
64. Schrag D, Weeks J. Costs and cost-effectiveness of colorectal cancer prevention and therapy. Semin Oncol 1999; 26: 561-8
65. Bang H. Medical cost analysis: application to colorectal cancer data from the SEER Medicare database. Contemp Clin Trials 2005; 26: 586-97
66. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604
67. Giuliani G, Lucioni C, Mazzi S, et al. Economic evaluation of oral capecitabine vs intravenous 5-fluorouracil plus leucovorin (Mayo regimen) in the treatment of advanced colorectal cancer [in Italian]. Pharmacoeconomics 2002; 4: 31-8
68. Murad AM, Augusto de Andrade C, Delfino C, et al. Pharmacoeconomic evaluation of tegafur-uracil (UFT) vs fluorouracil for the management of colorectal cancer in Brazil and Argentina. Clin Drug Invest 1997; 13: 90-8
69. Ron IG, Lotan A, Inbar MJ, et al. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs 1996; 7: 649-54
70. Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004; 33: 45-55
71. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-17
72. Cavallo MC, Gerzeli S, De Carli C, et al. The cost of treatment for advanced colorectal cancer: a retrospective comparison of five chemotherapy regimens used in a Northern Italy hospital [in Italian]. Pharmacoeconomics 2001; 3: 49-59
73. Nicholls C, Cassidy J, Freemantle N, et al. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone. J Drug Assess 2001; 4: 215-26
74. Nicholls C, Cassidy J, Freemantle N, et al. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Drug Assess 2001; 4: 255-63
75. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30
76. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-14
77. L'informatore farmaceutico 2003: annuario italiano dei medicamenti e dei laboratori. Italian directory of medicines and manufacturers. 63rd ed. 5 Vol. Milan: OEMF International SRL, 2003
78. National Institute for Health and Clinical Excellence. Colorectal cancer (metastatic): bevacizumab and cetuximab (technology appraisal TA118) [online]. Available from URL: http://www.nice. org.uk/ta118 [Accessed 2007 May 16]
79. National Institute for Health and Clinical Excellence. Colorectal cancer (advanced): irinotecan, oxaliplatin and raltitrexed (review) [technology appraisal TA118] (online). Available from URL: http://www.nice.org.uk/ta093 [Accessed 2007 May 16]
80. National Institute for Health and Clinical Excellence. Colorectal cancer: capecitabine and tegafur uracil (technology appraisal TA61) [online]. Available from URL: http://www.nice.org.uk/ta061 [Accessed 2007 May 16]
81. Jansman FGA, Sleijfer DT, Coenen JLLM, et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Safety 2000; 23: 255-78